CompanyGraphAt a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
5.88BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.21xvs all stocks
52-Week Change
345.12%vs all stocks
Market Capitalization
5.88BUSDvs all stocks (USD)
Enterprise Value
4.50BUSDvs all stocks (USD)
Forward P/E
-29.31xvs Biotechnology peers
Price to Book (MRQ)
16.53xvs Biotechnology peers
Enterprise to EBITDA
-28.95xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-35.72%vs Biotechnology peers
Return on Equity (TTM)
-94.70%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-237.54MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-144.77MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-45.63MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-166.31MUSDvs all stocks (USD)
Pre-tax Income
-183.79MUSDFY2025 · Dec 31, 2025Net Income
-183.79MUSDFY2025 · Dec 31, 2025EBIT
-178.31MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-155.35MUSDFY2025 · Dec 31, 2025Research & Development
117.67MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
48.64MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.96MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
5.48MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-183.79MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-158.68MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
257.84MUSDFY2025 · Dec 31, 2025Interest Paid
5.34MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-183.79MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
0.00USDFY2025 · Dec 31, 2025Stock-based Compensation
20.10MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.69MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
3.34MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-268.36MUSDFY2025 · Dec 31, 2025Sale of Investments
116.75MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-151.61MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
42.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-22.00MUSDFY2025 · Dec 31, 2025Other Financing Charges
-12.63MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
266.23MUSDFY2025 · Dec 31, 2025Shares Outstanding
104.04MSharesUpdated Jul 18, 2026Shares Short
14.52MSharesUpdated Jul 18, 2026Short Ratio
3.05daysvs all stocks
Short % of Shares Outstanding
11.01%vs all stocks
% Held by Insiders
1.33%vs all stocks
% Held by Institutions
65.98%vs all stocks
Total Cash (MRQ)
373.42MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.42USDUpdated Jul 18, 2026Total Debt (MRQ)
40.77MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1462xvs Biotechnology peers
Current Ratio (MRQ)
4.69xvs Biotechnology peers
Book Value per Share (MRQ)
2.68USDUpdated Jul 18, 2026Total Assets
440.10MUSDvs all stocks (USD)
Total Current Assets
419.32MUSDFY2025 · Dec 31, 2025Total Liabilities
107.77MUSDFY2025 · Dec 31, 2025Total Non-current Assets
20.78MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
41.08MUSDFY2025 · Dec 31, 2025Total Current Liabilities
66.70MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
257.84MUSDFY2025 · Dec 31, 2025Other Short-term Investments
153.76MUSDFY2025 · Dec 31, 2025Accounts Payable
5.35MUSDFY2025 · Dec 31, 2025Other Current Liabilities
40.91MUSDFY2025 · Dec 31, 2025Long-term Debt
40.58MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
496.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
0.00USDFY2025 · Dec 31, 2025Retained Earnings
-582.67MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
332.33MUSDvs all stocks (USD)
52-Week Low
7.96USDUpdated Jul 18, 202652-Week High
49.20USDUpdated Jul 18, 202652-Week Change
345.12%vs all stocks
Beta
2.21xvs all stocks
50-Day MA
30.98USDUpdated Jul 18, 2026200-Day MA
19.56USDUpdated Jul 18, 2026Avg 10-Day Volume
2.25MSharesUpdated Jul 18, 2026Avg 30-Day Volume
4.05MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-2.50USDUpdated Jul 18, 2026Other Income / Expense
-22.96MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $5.88B, above the global median of $1.15BNotable
Market cap (USD): 5,879,198,719Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Amneal Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Oruka Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen New Industries Biomedical Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule